Radiopharm Theranostics Ltd (RADX) Total Debt (2024 - 2026)

Radiopharm Theranostics (RADX) has reported Total Debt for 3 consecutive years, with $182827.2 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Debt fell 11.06% year-over-year to $182827.2 in Q2 2026; TTM through Jun 2026 was $182827.2, a 11.06% decrease from a year earlier, with the FY2026 full-year figure at $175045.2, down 99.45% from the prior year.
• Total Debt was $182827.2 for Q2 2026 at Radiopharm Theranostics, down from $205568.3 in the prior quarter.
• Over five years, Total Debt peaked at $29.5 million in Q4 2024 and troughed at $182827.2 in Q2 2026.
• A 3-year average of $7.5 million and a median of $212928.5 in 2024 frame the typical range for Total Debt.
• Across the five-year window, Total Debt decreased 6.68% in 2025 and dropped 11.06% in 2026, its largest moves.
• Over 3 years, Total Debt stood at $29.5 million in 2024, then tumbled by 99.3% to $205568.3 in 2025, then decreased by 11.06% to $182827.2 in 2026.
• The last three Total Debt figures came in at $182827.2 (Q2 2026), $205568.3 (Q2 2025), and $29.5 million (Q4 2024), per Business Quant data.